Stocktoria
Biofrontera Inc. BFRI
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-10-14
Biofrontera Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -27.2% | -46.1% | -66.6% | -64.8% | -104.6% |
| Net margin | -25.3% | -47.6% | -59.1% | -2.2% | -156.5% |
| FCF margin | -32.0% | -27.5% | -73.1% | -56.6% | — |
| Return on assets | -36.9% | -80.4% | -72.1% | -1.3% | -70.9% |
| Return on equity | -100.5% | -400.6% | -420.0% | -2.7% | -332.6% |
| Current ratio | 1.52 | 1.72 | 1.28 | 2.06 | 3.36 |
| Revenue growth | 11.7% | 9.5% | 18.8% | 19.0% | 27.9% |
Source: SEC EDGAR filings · CIK 0001858685 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.